FDA Brief

Warning letters Drugs

FDA warning letter to

My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD

High riskIssued Aug 25, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warned My Holistic Honey that its honey eye drops are an unapproved new drug sold with drug claims.

What happened

FDA reviewed the product label and the website https://myholistichoney.com/ in July 2025 and found "Holistic Honey EYE DROP" (also called "Jimerito Honey Eye Drops") offered for sale in the United States. The label and website claim the drops relieve dry eye, reduce inflammation, soothe irritation and help reduce the risk of long-term vision problems. FDA says these claims make it a drug, and it is not generally recognized as safe and effective and has no approved application.

What FDA found

  1. The label and website claims that the drops treat eye dryness, irritation and inflammation make the product a drug.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The product is not generally recognized as safe and effective for those uses, so it counts as a new drug.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. There is no FDA-approved application for the product, so selling it across state lines is illegal.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA asks the company to write within fifteen working days describing the specific steps taken to correct the violations and prevent them from happening again, with supporting documents, or to explain why the product is not in violation. The reply goes to CDER's Office of Unapproved Drugs and Labeling Compliance with the identifier 712052 in the subject line.

Who should pay attention

  • online sellers and marketplaces listing eye-care products
  • brands marketing honey or "natural" remedies with drug-like claims
  • importers and distributors of ophthalmic products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk